Overall, this preclinical study indicates that the PI3K δ-sparing inhibitor, MEN1611, could be a candidate for the treatment of NSCLC with an erlotinib/gefitinib-resistant phenotype and constitutive activation of the PI3K/AKT pathway. This evidence concerns the gene PIK3CB and non-small cell lung carcinoma.